Daily Newsletter

16 February 2024

Daily Newsletter

16 February 2024

Earlybird Health raises $185m to propel European healthcare ventures

The German health investor will use its AI Earlybird Eagle Eye platform to scout out promising startups and gather crucial insights.

Jenna Philpott February 15 2024

German health venture capital company Earlybird Health has raised $185m (€173m) to propel early-stage European healthcare ventures from initial stages to advanced technology nearing regulatory approval and commercialisation. 

The venture fund will focus on nurturing companies in various sectors such as digital health, diagnostics, medical devices, research and development tools, and biopharma. 

Several institutional investors in Europe participated in the fund, including the British Patient Capital, a commercial affiliate of the government-owned British Business Bank, and BARMER, a leading public health insurer in Germany. 

Earlybird will utilise its artificial intelligence (AI) platform named Earlybird Eagle Eye to identify promising startups and gather crucial insights. By offering market intelligence including competitor analyses and trend reports, the tool enhances companies’ deal flow.  

In the announcement accompanying the capital round, principal at Earlybird Christoph Massner said: “Eagle Eye will soon be the driver of a more effective, efficient, and inclusive deal sourcing and due diligence process for our investment teams. Earlybird Health is proud to set the standard for dynamic and informed deal flow in the European healthcare sector.” 

This follows uncertainty in the industry after two start-ups, Avail and Olive, closed their doors in November – signalling a potential end to the medtech Covid funding rush.  

The same month, Dutch health investor Gilde raised $804m, reassuring investors in the medtech field. The company, which has raised more than €1.7bn over the past three years over several different funds, said it will use the money to focus on lower mid-market healthcare companies. 

Carrying on into this year, Goldman Sachs Asset Management closed its first life sciences fund in January raising $650m, called West Street Life Sciences I. Approximately $90 million has already been committed to five companies: MOMA Therapeutics, Nested Therapeutics, TORL Biotherapeutics, Septerna and Rapport Therapeutics with focus areas including precision medicine, immunotherapy, and AI-driven oncology, among others. 

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.